Tyloxapol: Difference between revisions
No edit summary |
No edit summary |
||
| Line 94: | Line 94: | ||
}}</ref> |
}}</ref> |
||
Tyloxapol is the main active ingredient of the medical device Tacholiquin®. Tacholiquin is an expectorant designated for inhalation and instillation reaching the upper and lower airways. |
Tyloxapol is the main active ingredient of the medical device Tacholiquin®. Tacholiquin® is an expectorant designated for inhalation and instillation reaching the upper and lower airways. |
||
Other brand names of pharmaceutical products containing Tyloxpol are: Exosurf, Alevaire |
Other brand names of pharmaceutical products containing Tyloxpol are: Exosurf, Alevaire |
||
==References== |
==References== |
||
Revision as of 09:28, 30 October 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.209.660 |
| Chemical and physical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
  (what is this?) (verify) | |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.
With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]
Tyloxapol is the main active ingredient of the medical device Tacholiquin®. Tacholiquin® is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are: Exosurf, Alevaire
References
- ^ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.
- ^ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.
- ^ Drugs.com: Tyloxapol definition
- ^ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology. 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |